310 related articles for article (PubMed ID: 27481010)
1. Liquid Biopsies for Assessing Metastatic Melanoma Progression.
Huynh K; Hoon DS
Crit Rev Oncog; 2016; 21(1-2):141-54. PubMed ID: 27481010
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
Huang SK; Hoon DS
Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
Calapre L; Warburton L; Millward M; Ziman M; Gray ES
Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
[TBL] [Abstract][Full Text] [Related]
4. Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.
Busser B; Lupo J; Sancey L; Mouret S; Faure P; Plumas J; Chaperot L; Leccia MT; Coll JL; Hurbin A; Hainaut P; Charles J
Biomed Res Int; 2017; 2017():5986129. PubMed ID: 28484715
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
6. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
Alix-Panabières C; Pantel K
Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
[TBL] [Abstract][Full Text] [Related]
7. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.
Xu MJ; Dorsey JF; Amaravadi R; Karakousis G; Simone CB; Xu X; Xu W; Carpenter EL; Schuchter L; Kao GD
Oncologist; 2016 Jan; 21(1):84-94. PubMed ID: 26614709
[TBL] [Abstract][Full Text] [Related]
9. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.
Bidard FC; Madic J; Mariani P; Piperno-Neumann S; Rampanou A; Servois V; Cassoux N; Desjardins L; Milder M; Vaucher I; Pierga JY; Lebofsky R; Stern MH; Lantz O
Int J Cancer; 2014 Mar; 134(5):1207-13. PubMed ID: 23934701
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
Gingras I; Salgado R; Ignatiadis M
Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
[TBL] [Abstract][Full Text] [Related]
11. A headlight on liquid biopsies: a challenging tool for breast cancer management.
Massihnia D; Perez A; Bazan V; Bronte G; Castiglia M; Fanale D; Barraco N; Cangemi A; Di Piazza F; Calò V; Rizzo S; Cicero G; Pantuso G; Russo A
Tumour Biol; 2016 Apr; 37(4):4263-73. PubMed ID: 26790442
[TBL] [Abstract][Full Text] [Related]
12. The dynamic range of circulating tumor DNA in metastatic breast cancer.
Heidary M; Auer M; Ulz P; Heitzer E; Petru E; Gasch C; Riethdorf S; Mauermann O; Lafer I; Pristauz G; Lax S; Pantel K; Geigl JB; Speicher MR
Breast Cancer Res; 2014 Aug; 16(4):421. PubMed ID: 25107527
[TBL] [Abstract][Full Text] [Related]
13. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.
Vendrell JA; Mau-Them FT; Béganton B; Godreuil S; Coopman P; Solassol J
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146051
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.
Parimi S; Ko JJ
Expert Rev Anticancer Ther; 2017 Oct; 17(10):939-949. PubMed ID: 28737470
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer.
Gao Y; Zhu Y; Yuan Z
Int J Med Sci; 2016; 13(12):902-913. PubMed ID: 27994495
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the Cancer Genome in Blood.
Dawson SJ
Cold Spring Harb Perspect Med; 2019 Apr; 9(4):. PubMed ID: 29844219
[TBL] [Abstract][Full Text] [Related]
17. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.
Ignatiadis M; Lee M; Jeffrey SS
Clin Cancer Res; 2015 Nov; 21(21):4786-800. PubMed ID: 26527805
[TBL] [Abstract][Full Text] [Related]
19. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
[TBL] [Abstract][Full Text] [Related]
20. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
